Comparison of cytokine production in mice inoculated with messenger RNA vaccines BNT162b2 and mRNA‐1273

Two messenger RNA (mRNA) vaccines of BNT162b2 and mRNA‐1273 were licensed. The most common adverse event is regional pain at the injection site in 80%. As systemic reactions, fatigue and headache were noted in 40%–60% and febrile illness in 10%–40% of the recipients. To investigate the mechanism of adverse events, cytokine profiles were investigated in mice. Muscle tissue and serum samples were obtained on days 0, 1, 3, 5, and 7, and at 2 and 4 weeks after the first dose. The second dose was given 4 weeks after the first dose and samples were obtained. After inoculation with 0.1 mL of mRNA‐1273, IFN‐γ and IL‐2 were detected in muscle tissues and serum samples on day 1 of the second doses, and similar profiles were observed for IL‐4, IL‐5, and IL‐12 production. mRNA‐1273 induced higher levels of Th1 and Th2 cytokines. TNF‐α was induced in muscle tissues on day 1 of the first dose and enhanced on day 1 of the second dose after inoculation with BNT162b2 and mRNA‐1273. IL‐6 was also detected in muscle tissue on day 1 of the first dose, but it decreased after day 3, and enhanced production was demonstrated on day 1 of the second dose. Granulocyte colony‐stimulating factor in muscle tissues showed a similar profile. The induction of inflammatory cytokines in the mouse model is related to the cause of adverse events in humans, with a higher incidence of adverse events after the second dose.

[1]  T. Nakayama,et al.  Increased Production of Inflammatory Cytokines after Inoculation with Recombinant Zoster Vaccine in Mice , 2022, Vaccines.

[2]  L. Hartling,et al.  Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review , 2022, BMJ.

[3]  V. Anttila,et al.  Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice , 2021, Human vaccines & immunotherapeutics.

[4]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[5]  Nguyen H. Tran,et al.  Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. , 2020, Lancet.

[6]  OUP accepted manuscript , 2021, Clinical Infectious Diseases.

[7]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[8]  M. Cunningham,et al.  Multisystem Inflammatory Syndrome in Children (MIS-C), a Post-viral Myocarditis and Systemic Vasculitis—A Critical Review of Its Pathogenesis and Treatment , 2020, Frontiers in Pediatrics.

[9]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[10]  E. Walsh,et al.  Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates , 2020, The New England journal of medicine.

[11]  R. Baric,et al.  Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults , 2020, The New England journal of medicine.

[12]  A. Vojdani,et al.  Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases , 2020, Clinical Immunology.

[13]  Barney S. Graham,et al.  Rapid COVID-19 vaccine development , 2020, Science.

[14]  A. Amanullah,et al.  Myocardial injury and COVID-19: Possible mechanisms , 2020, Life Sciences.

[15]  Dae-Gyun Ahn,et al.  Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19) , 2020, Journal of microbiology and biotechnology.

[16]  Denisa Bojkova,et al.  Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China , 2020, The New England journal of medicine.

[17]  G. Leung,et al.  Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study , 2020, The Lancet.

[18]  Y. Kashiwagi,et al.  Long‐term regulation of local cytokine production following immunization in mice , 2018, Microbiology and immunology.

[19]  Robert Langer,et al.  Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. , 2017, Nano letters.

[20]  A. Didierlaurent,et al.  Adjuvant system AS01: helping to overcome the challenges of modern vaccines , 2017, Expert review of vaccines.

[21]  U. Eriksson,et al.  The Quest for New Approaches in Myocarditis and Inflammatory Cardiomyopathy. , 2016, Journal of the American College of Cardiology.

[22]  T. Nakayama.  An inflammatory response is essential for the development of adaptive immunity-immunogenicity and immunotoxicity. , 2016, Vaccine.

[23]  S. Ikeda,et al.  Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. , 2014, Internal medicine.

[24]  Y. Kashiwagi,et al.  Inflammatory responses following intramuscular and subcutaneous immunization with aluminum-adjuvanted or non-adjuvanted vaccines. , 2014, Vaccine.

[25]  E. Ledent,et al.  Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age. , 2013, The Journal of infectious diseases.

[26]  O. Levy,et al.  Developmental Biology of the Innate Immune Response: Implications for Neonatal and Infant Vaccine Development , 2009, Pediatric Research.

[27]  Andrew T. Kroger,et al.  Syncope after vaccination--United States, January 2005-July 2007. , 2008, MMWR. Morbidity and mortality weekly report.